Longeveron (LGVN) Other Non-Current Assets (2021 - 2026)

Longeveron (LGVN) recorded quarterly Other Non-Current Assets of $18000.0 in Q1 2026, down 89.77% quarter-over-quarter from $176000.0 in Q4 2025, and down 91.04% on a YoY basis from $201000.0 in Q1 2025.

Longeveron (LGVN) Other Non-Current Assets (2021 - 2026) Analysis & Trends

Longeveron's Other Non-Current Assets history runs 6 years deep, the most recent figure standing at $18000.0 for Q1 2026.

  • In Q1 2026, Other Non-Current Assets fell 91.04% year-over-year to $18000.0; the TTM figure through Mar 2026 stood at $18000.0 (down 91.04% YoY), while the FY2025 annual figure was $176000.0, down 12.87% from the prior year.
  • Other Non-Current Assets was $18000.0 for Q1 2026 at Longeveron, down from $176000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $247000.0 in Q1 2023 to a low of $18000.0 in Q1 2026.
  • Historically, Other Non-Current Assets has averaged $191142.9 across 5 years, with a median of $200500.0 in 2025.
  • The sharpest annual moves came in 2022 and 2026: Other Non-Current Assets jumped 37.85% in 2022, then tumbled 91.04% in 2026.
  • A 5-year view of Other Non-Current Assets shows it stood at $244000.0 in 2022, then fell by 20.9% to $193000.0 in 2023, then rose by 4.66% to $202000.0 in 2024, then fell by 12.87% to $176000.0 in 2025, then sank by 89.77% to $18000.0 in 2026.
  • The last three Other Non-Current Assets figures came in at $18000.0 (Q1 2026), $176000.0 (Q4 2025), and $178000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Non-Current Assets (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - 289.41 Mn
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 12.40 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - 60,000.00
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 1.26 Bn
9 Abivax 91.96 Bn 91.96 Bn - -
10 Longeveron 20.35 Bn 20.33 Bn 264,000.00 18,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 18,000.00
Dec 31, 2025 176,000.00
Sep 30, 2025 178,000.00
Jun 30, 2025 200,000.00
Mar 31, 2025 201,000.00
Dec 31, 2024 202,000.00
Sep 30, 2024 203,000.00
Jun 30, 2024 204,000.00
Mar 31, 2024 190,000.00
Dec 31, 2023 193,000.00
Sep 30, 2023 197,000.00
Jun 30, 2023 223,000.00
Mar 31, 2023 247,000.00
Dec 31, 2022 244,000.00
Dec 31, 2021 177,000.00